- Home
- Companies
- usa nevada
- t cell subtypes from naive t cells
Show results for
Refine by
T Cell Subtypes From Naive T Cells Suppliers Serving Usa Nevada
63 companies found
based inWoburn, MASSACHUSETTS (USA)
ImmunoDX, LLC (IDX) - formerly known as ImmunoDiagnostics - develops, manufactures and markets a wide range of specialty biologicals for Human T-cell Research/ Diagnostics, AIDS, HCV, HBV, TB, Cancer and Arthritis diagnostics and therapeutics ...
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T; Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo; Clear anti-cancer efficacy in an orthotopic model; Smaller number of 4th ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
The Celluris’ novel solution, named RfuCAR, was engineering in order to respond some challenges addressed by clinical trials around the world. RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
based inSan Francisco, CALIFORNIA (USA)
Prellis Biologics, Inc. utilizes its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. A key application is Prellis’ Externalized Immune System, EXIS, which through the creation of lymph node ...
based inSeattle, WASHINGTON (USA)
We believe we are entering a new era of medicine. The ability to modify genes and use cells as medicines provides new tools to meaningfully change the outcome of many human diseases. Early pioneers have made good progress, but most of what we can ...
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
based inHuntsville, ALABAMA (USA)
Founded in 2009 at the Hudson Alpha Institute for Biotechnology, iRepertoire was the first company to develop and commercialize immune repertoire sequencing technology and ...
When RNA is extracted for bulk repertoire sequencing, information related to the cognate pairing of BCR and TCR chains is lost. Our single cell service, iPair, is the first consumer-based service specifically designed for capturing physically paired ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid ...
based inCleveland, OHIO (USA)
Cellular Technology Limited (CTL) is a biotechnology company headquartered in Shaker Heights, a suburb of Cleveland, Ohio, with locations and distributors worldwide. We presently have around 180 full-time employees. Our company is family owned and ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
based inHillsborough, NEW JERSEY (USA)
LifeTein, located in Somerset, New Jersey, was founded in 2008 with a simple vision: understanding life sciences one protein at a time. This philosophy has formed the foundation of every peptide, protein, antibody, gene, and chemical project that we ...
based inPhiladelphia, PENNSYLVANIA (USA)
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
The injectable modality (AIM INJ) is an injectable pharmaceutical product of AIM nanoparticles decorated with antigen-specific peptides and co-stimulatory molecules appropriate for the disease being targeted. Based on specific size and ...
based inSan Carlos, CALIFORNIA (USA)
CellFE is a venture-backed company with a mission to make advanced therapies accessible to all by transforming the way gene therapies are manufactured. The company uses a microfluidics-based cell engineering platform that can be adapted universally ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
based inOxford, UNITED KINGDOM
Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford ...
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been ...
based inBerkeley, CALIFORNIA (USA)
Indee Labs is developing a non-viral, intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes with minimal perturbation. The technology is used by global ...
Hydropore™ is a simple, scalable and efficient way to accelerate the discovery, development and manufacturing of gene-modified cell therapies (GMCTs) such as T cell immunotherapies. This novel, non-viral technology utilizes the ...